1. Home
  2. XRTX vs HTCR Comparison

XRTX vs HTCR Comparison

Compare XRTX & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$2.19

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

HOLD

Current Price

$2.88

Market Cap

4.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
XRTX
HTCR
Founded
2011
2009
Country
Canada
Japan
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.4M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
XRTX
HTCR
Price
$2.19
$2.88
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.3K
30.1K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
87.84%
EPS Growth
N/A
414.29
EPS
N/A
N/A
Revenue
N/A
$30,407,229.00
Revenue This Year
N/A
$123.26
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.19
52 Week Low
$0.35
$0.15
52 Week High
$3.60
$3.97

Technical Indicators

Market Signals
Indicator
XRTX
HTCR
Relative Strength Index (RSI) 57.19 56.16
Support Level $2.00 $0.27
Resistance Level $2.24 $3.82
Average True Range (ATR) 0.11 0.24
MACD 0.02 0.08
Stochastic Oscillator 81.25 92.28

Price Performance

Historical Comparison
XRTX
HTCR

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.

Share on Social Networks: